NEW YORK (GenomeWeb News) – Agilent Technologies said today that it has reached an agreement with BIA Separations that gives it access to BIA Separations’ Convective Interaction Media bio-monolithic technology.
Agilent said it will use the technology to develop HPLC columns with strong and weak ion-exchange phases and a protein A phase.
Access to the technology will enable Agilent to provide "enabling solutions" for the separation of virus particles, plasmid DNA, antibodies and other large biomolecules, said Helen Stimson, Agilent's VP and GM of global columns and supplies solutions.
"This technology, when applied at the analytical scale, will improve bio-drug characterization in development and allow QA/QC and process control labs to better monitor and characterize the production of biologics,” she added.
The partnership will also allow BIA Separations "to focus its marketing and sales efforts on preparative and process scale bio-chromatography applications,” said Ales Strancar, managing director of Klagenfurt, Austria-based BIA.